Profluent, a biotechnology company that is using AI to design proteins, says it has demonstrated “scaling laws” in the performance of AI models for biology that are similar to those AI researchers ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ali Madani, PhD, CEO of Profluent, says there’s an urgent need to move away from the time-consuming slog of random therapeutic discovery and into artificial intelligence (AI)-based bespoke design.

Partnership leverages Profluent’s frontier AI models to take on one of genetic medicine’s hardest problems: designing personalized genomic interventions for rare disease patients. EMERYVILLE, Calif., ...

Collaboration combines Profluent's frontier AI platform with Lilly's leading capabilities in genetic medicines AI-designed recombinases aim to unlock kilobase-scale DNA editing capabilities across ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly (LLY.N), opens new tab worth up ‌to $2.25 billion to develop ...

Last year, Salesforce, the company best known for its cloud sales support software (and Slack), spearheaded a project called ProGen to design proteins using generative AI. A research moonshot, ProGen ...

Jeff Bezos has had quite a busy week, having just concluded his third venture capital investment in a promising artificial intelligence startup. This time, the recipient of Bezos’s largesse is a ...

California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25 billion, that will focus on gene-editing therapies. Profluent has attracted attention ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions ...